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ABSTRACT
INTRODUCTION: Treatment of chronic diseases is a long-lasting and ongoing process that requires contin-
uous pharmacotherapy. Adherence indicates the extent to which patient behaviour (in terms of medicine in-
take, diet compliance and change of life) corresponds to the advice received by a medical professional. 
AIM: The aim of this article is to study and analyse the opinion of pharmacists, working in hospital and 
community pharmacies, on patients’ level of adherence to the prescribed drug therapy and to identify the 
leading socioeconomic, pharmacotherapeutic and pharmacoeconomic factors affecting adherence in pa-
tients with chronic diseases. 
MATERIALS AND METHODS: This national study was conducted in May 2020. Anonymous individual 
questionnaires were distributed to Masters of Pharmacy and assistant pharmacists. The survey was con-
ducted online by a sociological method, using a Google form. Data was processed through software includ-
ed in the Google forms. Charts were created with MS Excel and MS Word.
RESULTS: The results confirm the European and global tendency towards a low level of patient adherence 
to drug therapies—84.7% of pharmacists responded that only half of the patients adhered to the therapy. 
Respondents reported the high price and low reimbursement rate of medicines as objective reasons for non-
purchasing medicinal products (79.8%). Our survey results indicate that adherence to therapy in patients 
with chronic diseases in Bulgaria remains a significant issue due to various socioeconomic and pharmaco-
therapeutic factors.
CONCLUSION: Adherence to the prescribed pharmacotherapy is crucial for achieving the therapeutic re-
sults.
Keyword: patient adherence, chronic diseases, drug therapies, socioeconomic and pharmacotherapeutic 
factors
INTRODUCTION
Treatment of chronic diseases is a long-lasting 
and ongoing process that requires continuous phar-
macotherapy. Adherence is a key issue for the proper 
management while non-adherence to the prescribed 
regimen increases morbidity and mortality. Despite 
that, long-term adherence to prescribed therapy has 
been found hard to achieve (1).
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Adherence indicates the extent to which patient 
behaviour (in terms of medicine intake, diet compli-
ance and change of life) corresponds to the advice re-
ceived by a medical professional. The patient is the 
one who decides how much to adhere to the pre-
scribed therapy (2). 
A report of the World Health Organisation 
(WHO) indicates that adherence to therapy by chron-
ically ill patients is about 50% in developed countries, 
whereas adherence in developing countries is lower 
(3). These are patients with properly prescribed med-
icines who take them but not in compliance with the 
regimen/plan given by the doctor or who do not take 
them at all, which has a negative impact on the ther-
apeutic efficacy. 
Studies by Coyle and Lee indicate that only 1/3 
of patients take their medicines as prescribed and 
from the rest, 1/3 sometimes adhere, and 1/3 never 
adhere to the prescription (4). Furthermore, there are 
difficulties with such patients who create their own 
regimen probably based on incorrect understanding 
of the drug therapy. In such cases it is very likely to 
overdose a medicine for “a faster effect and recovery” 
or to combine it with alternative methods to “aug-
ment” its effect (4).
A review of statistical data from the American 
Heart Association (AHA) has found that almost 50% 
of patients with cardiovascular diseases who are on 
a long-term therapy take their drugs in compliance 
with the prescribed treatment plan, 22% skip intake 
or take lower doses, which reduces the benefits of the 
therapy (5).
It has been estimated that approximately 125 
000 deaths per year in the USA are due to non-adher-
ence to therapy. Patients not adhering to their thera-
py use more healthcare resources compared to those 
who strictly perform the prescribed treatment. In the 
USA non-adherence costs an additional $100 billion 
to the healthcare system annually (5).
According to different studies worldwide, ad-
herence to therapy in asthma varies from 30% to 
80%. In the USA adherence in asthma patients is es-
timated to be over 40%, in France, Germany and Ita-
ly it is between 60% and 70% (6). The level of adher-
ence in patients with chronic obstructive pulmonary 
disease (COPD) is lower than other chronic diseases 
despite the severity of this disease. Data shows adher-
ence between 10% and 40% (7).
A factor influencing adherence to therapy in 
children is related to dependence on their parents to 
provide and apply the therapy (8).
In 2015, a study by Todorova and Tsvetkova re-
lated to therapy adherence in children with bronchi-
al asthma has analysed the role of parents as main 
actors responsible for daily adherence to the treat-
ment regimen. Results have shown that the majority 
of parents (68%) of children aged 6 to 12 report strict 
adherence to the prescribed treatment line while in 
the age between 13 and 16, adherence is 54%. Study 
data indicates insufficient parent compliance most-
ly due to lack of understanding of the therapy goals 
and fear of treatment-related side effects. It indicates 
that all medical professionals who participate in the 
different stages of treatment and follow-up should be 
involved in additional training of parents so they can 
understand their responsibility in achieving optimal 
management of paediatric bronchial asthma (9).
Elderly patients are more prone to adverse drug 
reactions and they also experience fear of drug inter-
actions, which reduces the level of adherence (8). Ac-
cording to Gaude’s studies between 25% and 50% of 
patients do not or cannot take the prescribed medic-
inal products correctly. Factors that should be con-
sidered are poor vision (20% of patients aged over 85) 
and hearing; strength and motor coordination; cog-
nitive abilities; depression and social isolation; co-
morbidities; polypharmacy and others (1,8).
AIM
The aim of this article is to study and analyse 
the opinion of pharmacists, working in hospital and 
community pharmacies, on patients’ level of adher-
ence to the prescribed drug therapy and to identi-
fy the leading socioeconomic, pharmacotherapeutic 
and pharmacoeconomic factors affecting adherence 
in patients with chronic diseases. 
MATERIALS AND METHODS
This national study was conducted in May 2020. 
Anonymous individual questionnaires were distrib-
uted to Masters of Pharmacy and assistant pharma-
cists. The questionnaire included 15 questions and 
collected information on the following aspects:
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  pharmacists’ career profiles (education, work 
experience, geographic location);
  level of patients’ adherence to the recommend-
ed treatment;
  factors influencing adherence to therapy.
The survey was conducted online by a socio-
logical method, using a Google form. Data was pro-
cessed through software included in the Google 
forms. Charts were created with MS Excel and MS 
Word.
RESULTS 
A total of 124 pharmacists participated in the 
survey of whom 74 (59.7%) assistant pharmacists and 
50 (40. 3%) Masters of Pharmacy. 
The majority of respondents, 96%, worked in 
community pharmacies and only 4% worked in hos-
pital pharmacies. 
Pharmacists’ work experience is shown in Ta-
ble 1.
Most of the pharmacists had less than 10 years 
of work experience, which indicated that young pro-
fessionals were more willing to take part in an on-
line survey compared to their colleagues with longer 
work experience. Distribution by territorial units is 
presented on Fig. 1. Five of the six regions in Bulgar-
ia were covered. Pharmacists from the North Eastern 
Region in Bulgaria represented the biggest group in 
the survey (81%). 
To the question if patients adhere to the drug 
therapy prescribed by doctors, 84.7% of pharmacists 
responded that only half of the patients adhered to 
the therapy (Fig. 2).
Data on Fig. 3 shows that price is the crucial fac-
tor when deciding whether to buy a medicinal prod-
uct. Respondents reported the high price and low re-
imbursement rate of medicines as objective reasons 
for non-purchasing medicinal products (79.8%). 
The second most common reason for non-pur-
chasing was patients’ opinion that more medicines 
have been prescribed than they needed (71.8%). A 
third reason was patients’ distrust in the efficacy of 
the prescribed medicinal products (39.5%). Another 
reason indicated by respondents was that, instead of 
Work Experience Number %
Less than 10 years 100 80.6
11–20 years 11 8.9
21–30 years 10 8.1
over 31 years 3 2.4
Table 1. Respondents’ work experience
Fig. 1. Distribution of respondents by region
Fig. 2. Patient adherence to the drug therapy
Fig. 3. Reasons why patients do not purchase the pre-
scribed medicinal products
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the prescribed medicines, the patients wanted to pur-
chase medicines they were previously using (34.7%), 
which is an example of poor compliance.
The primary reasons for low level of adherence 
to the treatment among patients with chronic diseas-
es identified by respondents were the high number of 
medicinal products (69.4%) as well as the high price 
of medicines and low percentage of reimbursement 
(66.9%) (Fig.4). 
Another reason was patients’ distrust in the 
benefits of the treatment (50.8%). 
Respondents placed adverse drug reactions 
next (42.7%), followed by causes that had similar 
percentages:
  insufficient information about the disease and 
treatment (37.9%);
  dosing frequency of the medicine (37.9%);
  patients’ personal reasons (35.5%); 
  long-term treatment (31.5%).
Finally, respondents indicated inconvenient 
route of administration (21.8%), inappropriate dos-
age form and healthcare professionals’ attitude to-
wards the patient (10.5%), as well as disease severi-
ty (7.3%).
The sum total is more than 100% as respondents 
provided more than one answer. 
Fig. 5 shows responses to the question: ‘Which 
is the key patient-related factor affecting non-adher-
ence to treatment?’ A total of 41.1% of respondents 
answered that the main cause for patients’ non-ad-
herence was that medicines were unaffordable; 27.6% 
of pharmacists expressed the opinion that patients 
were unaware of the importance of adherence to the 
regimen, while 20.2% reported a distrust in the ther-
apy when the medicine did not have the expected ef-
fect. Low educational level, age, sex, psychological 
factors and regimen leading to changes in patients’ 
daily routines were also identified as factors affecting 
adherence, but they were less significant according to 
the respondents. 
The respondents were given six statements and 
asked to indicate their degree of agreement. Fig. 6 
presents the results. 
Regarding the first statement pharmacists com-
pletely agreed (31.5%) or mostly agreed (47. 6%) that 
the high number of prescribed medicines reduced 
the likelihood that all of them would be taken. Less 
than 3% of respondents (2.4%) expressed slight dis-
agreement. A treatment regimen, which includes a 
small number of medicinal products, will promote a 
better adherence. 
Respondents completely agreed (35.5%) or 
mostly agreed (40.3%) with the statement that the 
more frequent the dosing, the less likely it was that 
all doses would be taken, whereas 8% disagreed with 
that. Often, patients subject to stress at work skip 
some of the doses, especially if the dose is divided 
into several intakes during the day. A dosage regi-
men consisting of fewer doses a day is characterised 
by higher adherence to the treatment and patients 
usually prefer once-daily dosing. 
Respondents unanimously agreed with the 
statements that good communication and trust in 
the doctor as well as providing pharmaceutical care 
Fig. 4. Reasons leading to low level of adherence to the 
treatment in patients with chronic diseases
Fig. 5. Patient-related factors leading to non-adherence
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influenced adherence positively and could result in 
improved adherence. 
Survey results regarding adherence in children 
and in patients over 65 were similar. Around 65% 
completely agreed and 25% mostly agreed with the 
suggested statements. Pharmacotherapy in children 
is characterised with a higher degree of adherence 
as parents are more concerned with their children’s 
health and more strictly adhere to the prescribed 
regimen. In people over 65 there are specific factors 
influencing adherence, such as polypharmacy, im-
paired vision, forgetfulness as well as higher sensitiv-
ity to ADR, etc.
DISCUSSION
The pharmacy is the main structural unit of the 
pharmacy system. It provides the population and the 
healthcare facilities with medicinal products, medi-
cal and sanitary materials, herbs, etc. 
According to the Medicinal Products in Hu-
man Medicine Act there are 2 types of pharmacies in 
Bulgaria:
  community pharmacy—serves outpatients;
  hospital pharmacy—serves inpatients (10). 
A pharmacist is the most accessible health-
care professional for patients. Chronically ill patients 
whose condition needs to be managed through drug 
therapy meet more often with the pharmacist than 
with any other healthcare professional. This provides 
pharmacists with the opportunity to assist in moni-
toring the condition and to advise patients to a see a 
doctor if a change in treatment is needed (11).
The above results confirm the European and 
global tendency towards a low level of patient adher-
ence to drug therapies. Poor adherence leads to seri-
ous consequences for people’s health and quality of 
life and increased healthcare costs. 
Factors causing poor adherence to therapy are 
numerous. According to Petkova and Popov (2015) 
five main factors influencing the process are related 
to: pharmacotherapy; patient’s attitude and condi-
tion; healthcare system; social factors; economic fac-
tors (8). Our results confirm them.
In recent years overprescribing and the use of 
numerous medicinal products have led to polyphar-
macy, which is becoming a serious issue that causes 
Fig. 6. Pharmacists’ perception of factors influencing adherence
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ADRs, interactions and non-adherence to the treat-
ment (5).
The results of our study show that: 
  Polypharmacy, high prices of medicinal prod-
ucts and the low reimbursement percentage re-
duce the adherence level.
  Non-adherence to the prescribed treatment can 
also be due to a deliberate decision taken by the 
patient.  
  Communication with patients helps identify 
their attitude towards the prescribed medicines 
and enhances the likelihood of adherence to the 
treatment.
  Information and instructions for use which pa-
tients have difficulty understanding affect ad-
herence so the factors that need to be consid-
ered are age, sex and education. 
  Multiple daily doses and long-term use of a 
medicine are prerequisites for non-adherence 
to therapy. 
Pharmaceutical prices are a fundamental is-
sue for health care since they are the third most im-
portant component in the healthcare budgets of EU 
member states. According to a report of the Europe-
an Parliament presenting the differences in costs of 
medicinal products in the EU, the costs for health 
care and medicines continue to rise as a percentage 
from the GDP across the EU. This creates problems 
regarding sustainability. There is also a constantly 
increasing need to limit growing healthcare costs, in-
cluding those for medicines, and to efficiently spend 
insufficient resources. Prices of medicinal products 
differ in EU member states: for a basket of 150 medi-
cines, average national prices vary by up to 25%. Pri-
mary factors leading to price differences include in-
come levels, national, and sometimes regional, regu-
latory pricing policies and health technology assess-
ment of medicinal products, regulatory approach-
es to wholesale and retail distribution and taxation 
on pharmaceuticals, in particular value-added tax 
(VAT) (12).
The selling price of medicinal products in Bul-
garia is higher mostly due to the lower percentage of 
the price that is reimbursed by public resources.
Among the opportunities for cutting pharma-
ceutical prices is a more active pro-generics policy of 
the government, which would lead to a budget opti-
misation and cost reductions for the NHIF (National 
Health Insurance Fund). According to BGPHARMA 
(Bulgarian Generic Pharmaceutical Association) the 
price of generic medicinal products is between 20% 
and 90% lower than the price of patented medicines. 
Such a policy can contribute to improving popula-
tion health, reducing the high co-payment rates for 
patients and enhancing access to new cost-effective 
drugs by saving public funds (13). 
CONCLUSION
Non-adherence to therapy is a worldwide prob-
lem. One of the key reasons for non-adherence in pa-
tients with chronic diseases is their lack of sufficient 
knowledge about the disease and need for treatment, 
which results in a poor disease control and increased 
economic burden due to the higher expenses. There-
fore, adherence to the therapy should be a key as-
pect and priority in the treatment of chronic diseas-
es, thus contributing to a better quality of life for pa-
tients and improving the long-term prognosis of the 
disease.
In conclusion, our survey results indicate that 
adherence to therapy in patients with chronic diseas-
es in Bulgaria remains a significant issue due to vari-
ous reasons. The leading factors, affecting adherence 
in patients with chronic diseases are socioeconomic 
(patients’ personal reasons related to education and 
incomes), pharmacotherapeutic (high number of 
medicinal products), pharmacoeconomic (high price 
of medicines and low percentage of reimbursement). 
Adherence to the prescribed pharmacotherapy 
is crucial for achieving the therapeutic results. Use of 
extended release dosage forms promotes better ad-
herence due to reducing the need for a multiple in-
take during the day. Other opportunities we see for 
improving adherence are active generic policy, re-
duction of VAT on medicinal products (it is currently 
20%, whereas the average VAT in Europe is 7.7% (EF-
PIA 2016)), improvement of communication skills of 
doctors and pharmacists, etc.
REFERENCES
1. Gaude G. Factors affecting non-adherence in bron-
chial asthma and impact of health education. Indi-
an J Allergy Asthma Immunol. 2011; 25(1):1-8.
2. Titorenkov. P. Adherence to therapy in patients 
with COPD. InSpiro. 2015;33(5):13-9.
24 Scripta Scientifica Pharmaceutica, 2020;7(2):18-24Medical University of Varna
Analysis of Factors Affecting Adherence to Therapy in Patients with Chronic Diseases
3. Sabaté E. Adherence to long-term therapies: Evi-
dence for action. World Health Organization. Ge-
neva. 2003; 1-194.
4. Coyle L, Lee K.The problem of protocol driv-
en costs in pharmacoeconomic analysis. Phar-
macoeconomics. 1998;14(4):357–63. doi: 
10.2165/00019053-199814040-00003.
5. Nashev D, Kostov K. Adherence to therapy in pa-
tients with COPD and asthma. InSpiro. 2015;(5):33.
6. Gillissen A. Patient’s adherence in asthma. J Phys 
Pharm. 2007; 58(5):205–22.
7. Sanduzzi A. Balbo P. Candoli P. Catapano GA. 
Contini P. Mattei A. et al, COPD: adherence to 
therapy. Multidiscip Respir Med. 2014; 9(1):60.
8. Petkova Е, Popov D. Compliance and adherence to 
treatment in bronchial asthma. InSpiro. 2015;(5):33.
9. Todorova A, Tsvetkova A, Dimitrov M. Paren-
tal compliance: implications for the management 
of bronchial asthma in children. World J Pharm 
Pharm Sci.2015; 4(4):288-98.
10. Medicinal Products in Human Medicine 
Act. Available at https://www.lex.bg/laws/
ldoc/2135549536 
11. Todorova A. Modern pharmaceutical approach-
es in uncontrolled patients with allergic rhinitis. 
Pharmaceutical Care. Varna; 2016.
12. Differences in Costs of and Access to Pharma-
ceutical Products. A report of the European Par-
liament from 2011. Available at https://www.
europarl.europa.eu/thinktank/en/document.
html?reference=IPOL-ENVI_ET(2011)451481 
13. Bulgarian Generic Pharmaceutical Association. 
Generic Drugs. Available at https://bgpharma.bg/
bg/generichni-lekarstva.html
